<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142255</url>
  </required_header>
  <id_info>
    <org_study_id>XH-19-008</org_study_id>
    <nct_id>NCT04142255</nct_id>
  </id_info>
  <brief_title>Explore Efficacy of FMT Treating Childhood ASD Patients</brief_title>
  <official_title>A Clinical Study to Explore the Efficacy of Fecal Mircobiota Transplantation (FMT) in the Treatment of Childhood ASD Patients With Gastrointestinal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy of fecal microbiota transplantation (FMT) in improving the
      gastrointestinal symptoms and autism symptoms in patients diagnosed as autism spectrum
      disorder (ASD) comorbid with gastrointestinal symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to reconstruct the intestinal micro-ecology of children with ASD by
      the interventional treatment of FMT. At the same time, combined with metagenomics and 16S
      rRNA sequencing techniques, the trial aims to study the efficacy of intestinal micro-ecology
      for the treatment of autism symptoms and the improvement of gastrointestinal problems and
      autism symptoms in autistic patients, and to explore potential new techniques for treating
      children with ASD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The Gastrointestinal Symptom Rating Scale (GSRS) is an interview-based rating scale consisting of 15 items for assessment of bowel function, which refers to the period of the previous week and requires a short time to fill and has easy-to-understand questions on gastrointestinal symptoms. Changes in the Gastrointestinal Symptom Rating Scale (GSRS) before and after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Childhood Autism Rating Scale (CARS)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The CARS is a 15-item measure that clinicians complete based on observations from the child and subsequent interviews with the caregivers.The total score on the CARS reflects the symptom level of ASD with lower scores indicating minimal ASD symptoms and higher scores representing severe ASD symptoms. Changes in the Childhood Autism Rating Scale (CARS) before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Stool Records (DSR)</measure>
    <time_frame>From the treatment period to Week 12</time_frame>
    <description>The Daily Stool Records (DSR) is a self-designed questionaire to record each participant's stool per day during the study. Changes in the Daily Stool Records (DSR) before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Safety and Tolerability refer to treatment-related adverse events as assessed by CTCAE v5.0 in the 12-week observation after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Quotient/Intelligence Quotient Scale (DQ/IQ)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The (DQ/IQ) is evaluated by specialists in an intelligence test designed for children. Three versions of the intelligence test are the Gesell Developmental Schedules, the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) and the Wechsler Intelligence Scale for Children-Revised (WISC-R), which are selected according to each participant's age. Changes in the Developmental Quotient/Intelligence Quotient Scale (DQ/IQ) before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autism Diagnostic Observation Schedule (ADOS)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The ADOS is a structured play session conducted by clinicians, which includes a series of social communication and play &quot;presses&quot; to diagnose ASD. For younger children, social interest, joint attention, communication, symbolic play, and repetitive behaviors are assessed. Changes in the Autism Diagnostic Observation Schedule (ADOS) before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Responsiveness Scale (SRS)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The SRS measures the severity of social interaction impairments in ASD populations, sensitive between 3 to 18 years of age.It provides an impression of observed social impairments, assessing domains of communication, social interactions, and repetitive and stereotyped behaviors and interests. Changes in the Social Responsiveness Scale (SRS) before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions-Improvement (CGI-I) Scale</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The CGI-I assesses how much the patient's condition has improved or worsened relative to a baseline state, ranging from 1 (very much improved) to 7 (very much worse), and is recommended for all clinical trials involving participants with ASD.Improvement was defined as a score of 3 (minimally improved) or lower. Changes in the Clinical Global Impressions-Improvement (CGI-I) Scale before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Safety Assessed Through Adverse Events</measure>
    <time_frame>[16, 20, 24 weeks]</time_frame>
    <description>Long Term Safety refers to treatment-related as assessed by CTCAE v5.0 after the 12-week study. Evaluation of safety telephone follow-up after 12 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Head Magnetic resonance imaging (MRI)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Head MRI is used to detect the structure of the brain. Changes in the head MRI results of the subject before and after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Children's Dietary Diversity Questionnaire</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Children's Dietary Diversity Questionnaire is a scale consisting of 8 categories of food each scoring from 0 to 2 based on the frequency. Changes in the subject's dietary diversity questionnaire results before and after treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ASD Accompanied by Moderate to Severe Gastrointestinal Symptoms</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects will be enrolled in this arm to receive FMT treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with ASD. Diagnostic criteria: diagnosed by pediatric psychiatrists
             in accordance with the criteria in the Fifth Edition of Diagnostic and Statistical
             Manual of Mental Disorders (DSM-V), Autism Diagnostic Observation Schedule (ADOS) and
             Autism Diagnostic Interview-Revised (ADI-R);

          2. Patients with moderate to severe gastrointestinal symptoms which are not
             life-threatening and do not require immediate surgery;

          3. Patients aged 3-17 years, male or female;

          4. Patients who are suitable for receiving oral FMT capsules, and able to swallow the
             capsules without chewing;

          5. Patients who are able to complete the study as required by the trial protocol;

          6. Patients without known immunodeficiency diseases;

          7. Subjects and/or their guardians are able to fully understand the informed consent of
             the trial, and voluntarily sign the informed consent form.

        Exclusion Criteriaï¼š

          1. Patients diagnosed with severe malnutrition;

          2. Patients depend on tube feeding (liquid food);

          3. Patients with a serious gastrointestinal disease requiring immediate treatment (or
             life-threatening);

          4. Patients with primary immunodeficiency disease during screening;

          5. Patients with a single-gene disorder;

          6. Patients with a history of severe allergies;

          7. Patients with severe fever and/or serious infection within 7 days prior to enrollment;

          8. Patients with renal insufficiency and liver dysfunction (or creatinine &gt; 2 mg/dl,
             direct bilirubin &gt; 2 mg/dl);

          9. Subjects with congenital or acquired immunodeficiency or immunosuppression (e.g.,
             neoplastic disease or organ transplant) who have received or are undergoing
             chemotherapy, or have been diagnosed with HIV;

         10. Patients with inflammatory bowel disease, celiac disease, large intestine irritation
             or eosinophilia, esophagitis, eosinophilic gastroenteritis or similar diseases;

         11. Subjects with severe sensory or motor disorders (e.g., blindness, deafness, seizures,
             cerebral palsy);

         12. Patients who are participating in other clinical studies, or have received
             interventions in other interventional clinical studies within 4 weeks prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Li, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua hospital Affilated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Li, Professor</last_name>
    <phone>+86-21-25077461</phone>
    <email>feili@shsmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShanghaiXinhua</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Li, Director</last_name>
      <email>feili@shsmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

